Genetically controlled variation is well established for cholinesterase in human serum, now known as acylcholine acylhydrolase (A.C.A.H., Enzyme Commission No. 3.1.1.8). Stimulus for investigation of variants of the enzyme arose from the observation that one genetic variant designated as atypical was responsible for prolonged apnoea following a standard dose of the muscle relaxant, succinylcholine (Kalow and Staron, 1957) . Details of classification of phenotypes and genotypes for variants of cholinesterase and their relation to succinylcholine-sensitivity are summarized elsewhere (Motulsky, 1964; Lehmann and Liddell, 1964; Simpson and Kalow, 1966) .
The atypical variant of the enzyme is recognized by a low percentage inhibition of activity by dibucaine (known as dibucaine number or DN) when benzoylcholine is used as substrate compared to high inhibition for the usual type. The two forms of enzyme are controlled by two allelic genes known as Ela (for the atypical) and Elu (for the usual variant). Heterozygotes (ElUEla) are recognized by an intermediate DN. Subsequently, Liddell, Lehmann, and Silk (1962) and Hodgkin, Giblett, Levine, Bauer, and Motulsky (1965) described serum with no enzyme activity towards benzoylcholine, the gene for which the former authors named 'silent' (Els). Goedde, Gehring, and Hofmann (1965a, b) , however, have evidence for minimal activity with benzoylcholine from sera from two subjects who were thought to be homozygous for the 'silent' gene. There is evidence for allelism of the Els gene with Ela and Elu genes (Simpson and Kalow, 1964) .
Differential inhibition by sodium fluoride combined with dibucaine inhibition has distinguished a third variant of the enzyme known as 'fluoride resistant' resulting from a gene known as Elf, with evidence that it is allelic to El and E., (Harris and 264 Whittaker, 1961,1962 In addition to enzyme variation controlled by the four alleles at the E1 locus, Harris, Robson, GlenBott, and Thornton (1963b) have described a variant controlled by a dominant gene at a second locus known as E2 and recognized by differences in migration during starch gel electrophoresis (Harris, Hopkinson, and Robson, 1962) . The phenotypes at the E2 locus are known as C5-for the commonly occurring type and C5 + for the dominant variant, and are not related to succinylcholine-sensitivity. Other rare electrophoretic variants have been reported (Neitlich, 1966; Ashton and Simpson, 1966) .
The description of the following family ascertained through an ElfEls propositus, who had had prolonged apnoea after a standard dose of succinylcholine, is reported here as a second observation of this rare heterozygote (the first is described by Whittaker, 1967) and as additional evidence that the Elf gene is at the E1 locus.
Methods and Material
Cholinesterase activity was measured spectrophotometrically using benzoylcholine as substrate under standard conditions at 260 C. (Kalow and Lindsay, 1955 ) and expressed for convenience as micromoles of acetylcholine hydrolysed by one ml. serum at 370 C. during one hour. Percentage inhibition of activity by dibucaine (DN) and sodium fluoride (FN) were determined under conditions described by Kalow and Genest (1957) and Harris and Whittaker (1961) . Classification of phenotypes at E1 locus were made according to Table I in a paper by Simpson (1966) . All determinations were made at least in duplicate.
Classification of phenotype at the E2 locus was made after one-dimensional vertical starch gel electrophoresis at pH 5-3, using a discontinuous buffer system as described by Harris, Hopkinson, Robson, and Whittaker (1963a (Harris and Whittaker, 1962; Liddell, Lehmann, and Davies, 1963; Lehmann and Liddell, 1964; Whittaker, 1967; N. E. Simpson, 1967, unpublished data Whittaker (1967) 3 5 5
N. E. Simpson (1967, unpub- lished data)
11 17
17 Total observation of five F homozygotes (Liddell et al., 1963; Simpson and Kalow, 1965; Griffiths, Davies, and Lehmann, 1966 
